Abstract No. 615 Lusutrombopag is a safe and efficacious treatment option for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures: integrated analysis of two phase 3 trials
Lusutrombopag (LUSU) is an oral, small molecule thrombopoietin receptor agonist approved in Japan and US for treatment of thrombocytopenia (TCP), and in EU for severe TCP, associated with chronic liver disease (CLD) in patients undergoing planned invasive procedures (IPs). This integrated analysis assessed the consistency of the efficacy and safety of LUSU clinical trial data across a larger population.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: R. Brown, M. Imawari, N. Izumi, Y. Osaki, T. Ochiai, T. Kano, R. Bentley, M. Peck-Radosavljevic Tags: Scientific e-Poster Source Type: research
More News: Clinical Trials | Japan Health | Liver | Liver Disease | Radiology | Thrombocytopenia | Urology & Nephrology